Its results showed that KRAS mutation was significantly associated with worse OS and disease-free survival (DFS) in early stage NSCLC, and with inferior outcomes of EGFR-TKIs treatment and chemotherapy. This evidence concerns the gene KRAS and non-small cell lung carcinoma.